Cumberland Pharmaceuticals Inc. announced on October 13 2025 that it has added its antibiotic Vibativ (telavancin) to a national group purchasing agreement with Premier, Inc. The product will be available to Premier members under pre‑negotiated pricing and terms effective October 1 2025, with options for a 12‑vial carton and a newly introduced 4‑vial Starter Pak.
The addition expands Premier’s portfolio of high‑margin specialty pharmaceuticals and provides members with cost‑effective access to a potent antibiotic. By securing this contract, Premier strengthens its supply‑chain services revenue stream and enhances its value proposition to healthcare providers seeking reliable pricing for critical medications.
Strategically, the deal positions Premier to capture a share of the antibiotic market, demonstrates its ability to secure new contracts in a competitive GPO landscape, and may pave the way for further collaborations with other specialty pharmaceutical companies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.